Valeant's online promotional material has once again triggered a letter from FDA. This time the agency says a webpage for Zovirax overstates the efficacy of the herpes drug and makes unsubstantiated superiority claims.
In Financings of the Fortnight, Idenix will forge ahead with HCV combo work following Novartis’ departure. Plus news on recent financial activity by Mersana Therapeutics, Hyperion Therapeutics, Atterocor and Exelixis.
